{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "NTRA",
  "name": "Natera, Inc.",
  "url": "https://frontierpicks.com/dossiers/NTRA/",
  "json_url": "https://frontierpicks.com/dossiers/NTRA.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "Natera's shares are more likely to lag the S&P 500 into early 2027, because an abrupt CEO change on 5 November 2026 outweighed a revenue beat and raised guidance. The Q4 report, estimated for late February 2027, tests Signatera growth under new CEO Solomon Moshkevich.",
  "invalidation_trigger": "A daily close above $363.76, the 2026-11-05 close before the third-quarter report, which would show the shares recovering the post-report loss and leading the S&P 500. Preliminary 2026 revenue above the $3.035 billion top of the guide would also show the shares leading.",
  "catalyst_date": "2026-12-08",
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "Natera, Inc. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001604821/000160482126000032/ntra-20260930xex991.htm",
      "date": "2026-11-05"
    },
    {
      "title": "Natera, Inc. - Form 10-Q - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001604821/000162828026071145/ntra-20260930.htm",
      "date": null
    },
    {
      "title": "Natera promotes Solomon Moshkevich to CEO",
      "url": "https://www.medtechdive.com/news/natera-promotes-solomon-moshkevich-to-ceo/874022/",
      "date": "2026-11-06"
    },
    {
      "title": "Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer",
      "url": "https://www.natera.com/company/news/natera-announces-clinical-collaboration-with-incyte-on-interventional-phase-ii-study-in-colorectal-cancer/",
      "date": null
    },
    {
      "title": "Natera, Inc. - Form S-3ASR - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001604821/000110465926125441/tm2629518-1_s3asr.htm",
      "date": "2026-11-12"
    },
    {
      "title": "Natera (NTRA) Q3 2026 Earnings Call: MRD Growth and $6 Billion 2029 Target",
      "url": "https://www.tradingkey.com/news/transcripts/262285650-",
      "date": null
    },
    {
      "title": "Piper Sandler reiterates Natera stock rating on CEO transition",
      "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-reiterates-natera-stock-rating-on-ceo-transition-93CH-5008319",
      "date": null
    },
    {
      "title": "Media Registration Now Open: San Antonio Breast Cancer Symposium 2026, December 8-11",
      "url": "https://www.aacr.org/about-the-aacr/newsroom/media-advisories/media-registration-now-open-san-antonio-breast-cancer-symposium-2026-december-8-11/",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Q3 2026 revenue was $794.0 million, up 34.1% from $592.2 million; about 339,500 oncology tests were processed, up 60.9%.",
      "source": "Natera Q3 2026 results release, 8-K Exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Full-year 2026 revenue guidance was raised to $3.005–$3.035 billion from $2.85–$2.91 billion; 2026 cash flow is guided to be positive.",
      "source": "Natera Q3 2026 results release, 8-K Exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Q3 2026 loss per share was $0.42 against a $0.29 estimate; revenue beat the $704.9 million estimate.",
      "source": "Benzinga, 2026-11-05",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Clinical MRD units were about 316,000, up 56% from 202,000 and up about 33,000 from Q2; Signatera's average selling price was about $1,290.",
      "source": "Natera Q3 2026 earnings call",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Steve Chapman resigned as CEO effective November 5, 2026; Solomon Moshkevich, a 15-year Natera executive, was named CEO.",
      "source": "Natera Q3 2026 10-Q; MedTech Dive 2026-11-06",
      "as_of": "2026-11-06"
    },
    {
      "claim": "JPMorgan lowered its target to $405 (Overweight), Evercore ISI to $400 (Outperform) and Baird to $403 (Outperform).",
      "source": "Benzinga, 2026-11-06 and 2026-11-09",
      "as_of": "2026-11-09"
    },
    {
      "claim": "Natera and Incyte agreed a Phase II colorectal cancer trial of INCA33890 that enrols Signatera MRD-positive patients and uses Signatera as a primary and secondary endpoint.",
      "source": "Natera press release, 2026-11-10",
      "as_of": "2026-11-10"
    },
    {
      "claim": "Natera registered up to 68,023 shares for resale by holders of a private company it acquired under a merger agreement of November 2, 2026; 45,533 shares were issued at closing.",
      "source": "Natera Form S-3ASR, 2026-11-12",
      "as_of": "2026-11-12"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "value_musd": 794,
              "yoy_pct": 34.1
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-07",
              "restated": null,
              "value_musd": 752.8,
              "yoy_pct": 37.7
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "value_musd": 696.6,
              "yoy_pct": 38.8
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-27",
              "restated": null,
              "value_musd": 665.5,
              "yoy_pct": 39.8
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-07",
              "restated": null,
              "value_musd": 592.2,
              "yoy_pct": 34.7
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-08",
              "restated": null,
              "value_musd": 546.6,
              "yoy_pct": 32.2
            }
          ]
        },
        "gross_margin": {
          "status": "not reported"
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "pct": -8.6
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-07",
              "restated": null,
              "pct": -10.1
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-08",
              "restated": null,
              "pct": -13.4
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-27",
              "restated": null,
              "pct": -3.4
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-07",
              "restated": null,
              "pct": -16.5
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-08",
              "restated": null,
              "pct": -20.2
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": -59.6
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "four_quarters_end": "2026-09-30",
          "value_musd": -59.9,
          "four_quarters_musd": -164.7
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 212.8
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 160.3
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 52.5
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "base_end": "2025-09-30",
          "pct": 5
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 1097.2
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 80.3,
          "composition": "short-term borrowings"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 1016.9
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 52.4,
          "yoy_pct": 37
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 471.4
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 91.7
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 1869.6
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "value_musd": 46269.5
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "value_musd": 45252.6
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "multiple": 15.6
        },
        "ev_ebit": {
          "status": "not meaningful"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "multiple": 24.7
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-31",
          "basis_filed": "2026-11-05",
          "pct": 0.1
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 4.04,
      "days_to_cover": 3.4,
      "change_pct": -7.9
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 104832482.94,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 365591936.48,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\n\nNatera's shares are more likely to lag the S&P 500 over the next three months. The business keeps growing fast, but the abrupt change of chief executive on 2026-11-05 has kept the shares down. The fourth-quarter report, estimated for late February 2027, is the next full test of Signatera growth under new CEO Solomon Moshkevich, and it lands at the far end of that three-month window.\n\nThe rating is Low because the shares have not recovered from the post-report drop. They closed at $310.67 on 2026-11-06, the first session after the report. Over the next three sessions they closed between $311.98 and $320.39. The close of $319.82 on 2026-11-11 sits below the 50-day moving average of $379.91.\n\nThe business numbers did not weaken. Natera's 2026-11-05 release put third-quarter revenue at $794.0 million, up 34.1% from $592.2 million, against Benzinga's $704.9 million estimate. The company raised 2026 revenue guidance to $3.005–$3.035 billion from $2.85–$2.91 billion. The loss of $0.42 per share was wider than Benzinga's $0.29 estimate. MedTech Dive reported on 2026-11-06 that TD Cowen's Dan Brennan said \"the immediacy of the move further created some initial angst from investors.\"\n\nThe price shows the market has given back the October run-up while broker targets stay high. On 2026-11-11 the shares closed 26.9% below the 52-week intraday high of $437.41 set on 2026-10-06. After the report, JPMorgan's target was $405, Evercore ISI's $400 and Baird's $403.\n\nTwo company events followed the report, and neither changes the case. On 2026-11-10 Natera announced a clinical collaboration with Incyte. On 2026-11-12 it filed a resale prospectus for up to 68,023 shares issued to buy a private company it did not name.\n\n## Bull Case\n- **Signatera unit growth is speeding up.** Management said on the 2026-11-05 call that clinical molecular residual disease (MRD) tests reached about 316,000 in Q3, up 56% from 202,000. The gain of about 33,000 over Q2 was the second quarter in a row above 30,000.\n- **Price per test is rising.** On the same call, management put Signatera's average selling price at about $1,290 in Q3, up from $1,271 in Q2.\n- **Drug developers design trials around Signatera.** Natera said on 2026-11-10 that Incyte's Phase II trial of INCA33890 in stage 2 and 3 colorectal cancer will enrol patients who test MRD-positive on Signatera after surgery and chemotherapy. Signatera is both a primary and a secondary endpoint.\n- **Brokers kept positive ratings after the drop.** JPMorgan kept Overweight with a $405 target and Evercore ISI kept Outperform with a $400 target on 2026-11-06, per Benzinga. Baird kept Outperform with a $403 target on 2026-11-09, per Benzinga. Piper Sandler reiterated Overweight and a $363.50 target on 2026-11-06, per Investing.com.\n- **The new CEO is a long-time insider.** MedTech Dive reported on 2026-11-06 that Moshkevich spent 15 years at Natera and ran clinical diagnostics. BNP Paribas's Navann Ty said the promotion \"should provide some continuity.\"\n- **Cash covers the spending plan.** Cash, cash equivalents and restricted cash were $1,097.2 million at 2026-09-30, against $80.3 million of debt. Natera's Q3 release guides 2026 cash flow to be positive.\n\n## Bear Case\n- **The CEO left on results day.** Steve Chapman resigned as CEO, President and director effective 2026-11-05 after more than seven years, per the Q3 10-Q, which reports no disagreement. He stays on as a consultant and adviser to the board. The company gave no reason beyond timing.\n- **Losses were wider than forecast.** The Q3 loss of $0.42 per share missed Benzinga's $0.29 estimate. The net loss was $59.9 million, per the 2026-11-05 release.\n- **Gains from revenue-estimate changes are shrinking.** Changes in revenue estimates added about $32.3 million in Q3 2026, against $52.3 million in Q2 2026 and $55.1 million in Q3 2025, per the Q3 release and 10-Q. The Q3 amount lifted gross margin by 1.5 percentage points.\n- **Broker targets moved down.** JPMorgan cut its target to $405 and Evercore ISI to $400 on 2026-11-06, per Benzinga. Baird's $403 target of 2026-11-09 was also a cut, per Benzinga.\n- **Senior managers sold shares just before the report.** SEC Form 4 filings show that on 2026-11-02 Moshkevich sold 3,419 shares at an average of $409.77 and Chapman sold 3,801 at $411.80, both under Rule 10b5-1 trading plans. A Rule 10b5-1 plan sets a schedule of sales in advance.\n\n## Setup & Price Structure\nThe shares closed at $391.03 on 2026-11-04 and fell to $310.67 on 2026-11-06, per adjusted daily closes. The close of $319.82 on 2026-11-11 is below the 50-day moving average of $379.91 and above the 200-day moving average of $270.49.\n\nThe price context puts the three-month change at 2.9%, measured from a close of $310.78 on 2026-08-13. In other words, the October run-up has been fully reversed. The 52-week intraday high is $437.41, set on 2026-10-06. The 52-week closing low is $182.65, set on 2026-03-27.\n\nInsiders sold into the run-up and kept selling after the drop, all under 10b5-1 trading plans. On 2026-11-02, seven officers and directors sold at average prices between $394.97 and $411.80, per SEC Form 4 filings. Director Jonathan Sheena sold 3,150 shares at an average of $316.00 on 2026-11-06, per a Form 4 filed on 2026-11-10.\n\n## Catalyst Calendar\n\n- **2026-12-08:** San Antonio Breast Cancer Symposium, December 8–11, 2026; Natera has not announced any Signatera abstracts. Breast cancer is one of Signatera's largest monitoring markets; new data there would be the first clinical update under the new CEO.\n- **~2027-01-11 (est.):** JPMorgan Healthcare Conference, Moshkevich's first major investor appearance as CEO. Shows whether the new CEO keeps the $6 billion 2029 revenue goal and whether 2026 revenue is tracking above or inside the $3.005–$3.035 billion guide.\n- **~2027-02-25 (est.):** Q4 2026 report and 2027 guidance. Shows whether Signatera keeps adding more than 30,000 clinical units a quarter and whether growth holds as gains from revenue-estimate changes shrink.\n\n## What Would Change Our Mind\n\nA daily close above $363.76, the 2026-11-05 close before the third-quarter report, which would show the shares recovering the post-report loss and leading the S&P 500. Preliminary 2026 revenue above the $3.035 billion top of the guide would also show the shares leading.\n\n## Correlation Notes\nNatera trades with other cancer-diagnostics stocks, especially companies selling MRD and liquid-biopsy tests such as Guardant Health. Medicare coverage decisions and payer news on MRD testing tend to move these stocks together. The 2026-11-06 drop was specific to Natera: it followed the CEO change and the wider loss. Benzinga listed DraftKings and Atlassian among other large stocks falling in that day's pre-market session for their own reasons. As a fast-growing healthcare company that is not yet profitable under GAAP, Natera also tends to move with investors' appetite for growth stocks.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T16:56:48+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}